Please login to the form below

Not currently logged in
Email:
Password:

Kala Pharma appoints Fovea founder Bernard Gilly to board

He previously formed the company that became Sanofi’s ophthalmology business

Dr Bernard Gilly, founder and CEO of Sanofi-owned Fovea, has joined the board of Kala Pharmaceuticals.

He brings years of experience in eye treatment to Kala, which is developing mucosal penetrating products in a number of ophthalmic diseases.

“Dr Gilly is a seasoned entrepreneur in the biotechnology industry having spent over 20 years building and investing in leading life science companies,” said Dr Guillaume Pfefer, Kala's president and CEO.

“His track record and expertise in the ophthalmology space is an invaluable addition to Kala as we advance our pipeline of transformative ophthalmic products into the clinic.”

Dr Gilly, along with Professor Jose Sahel and Pierre Belichard, set up Fovea in 2005. The company was acquired by Sanofi in 2009, becoming the French pharma firm's ophthalmology division.

Prior to his involvement with Fovea, Dr Gilly was a venture partner with Sofinnova Partners from 2000 to 2005.

He also served as a co-president and VP of R&D of Sanofi Pasteur and VP of R&D of BioMérieux.

His other entrepreneurial efforts include helping to found several biotech companies, including Domain Therapeutics, WebSurg, Kutexis, GenSight Biologicals, Pixium Vision and Enterome. He currently serves as chair at the latter three companies.

29th November 2012

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics